Platelet Disorder Clinical Trials

2 recruiting

Frequently Asked Questions

Common questions about Platelet Disorder clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 1

Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency

Inherited Bone Marrow Failure SyndromeFamilial Platelet Disorder With Predisposition to Myeloid Malignancies
National Cancer Institute (NCI)75 enrolled1 locationNCT06090669
Recruiting

ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

ThrombophiliaThrombosisSickle Cell Disease+10 more
American Thrombosis and Hemostasis Network3,000 enrolled71 locationsNCT04398628
Recruiting
Phase 1

Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder

RUNX1 Familial Platelet Disorder
M.D. Anderson Cancer Center4 enrolled1 locationNCT06414889
Recruiting
Phase 2

Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder

Familial Platelet DisorderHematopoietic
M.D. Anderson Cancer Center6 enrolled1 locationNCT06261060
Recruiting

Observational Study of Platelet Dysfunction Assessed by Thromboelastography in Cardiovascular Surgery (DISPLATEG)

Cardiac SurgeryBlood Platelet Disorders
Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León180 enrolled1 locationNCT06961175
Recruiting

Diagnosis and Phenotype Characterisation Using Genomics in Patients With Inherited Bone Marrow Failure (IBMDx Study)

Hematologic DiseasesInherited BMF SyndromeInherited Platelet Disorder
Peter MacCallum Cancer Centre, Australia350 enrolled1 locationNCT05196789
Recruiting

Preoperative Hemogram Parameters and BRAF Molecular Test Detected by Bethesda 3 Cytology.

BRAF V600EThyroid NoduleBlood Platelet Disorder+1 more
Saglik Bilimleri Universitesi120 enrolled1 locationNCT06539702
Recruiting

Towards Improved Diagnostics for Suspected Platelet Function Disorders

Platelet Function DisorderPlatelet DisorderThrombocytopathy
Region Stockholm140 enrolled1 locationNCT05985668